 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...63646566676869707172737475» |
- |||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration (clinicaltrials.gov) - May 21, 2014
P1/2, N=100, Completed, Sponsor: Arshad Khanani
Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Biomarker: Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion (clinicaltrials.gov) - May 20, 2014
P=N/A, N=50, Active, not recruiting, Sponsor: St. Marianna University School of Medicine
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Efficacy and Safety of Lucentis (clinicaltrials.gov) - May 14, 2014
P4, N=80, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (clinicaltrials.gov) - May 14, 2014
P1/2, N=100, Not yet recruiting, Sponsor: Southern California Desert Retina Consultants, MC
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: LucERG: Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD (clinicaltrials.gov) - May 13, 2014
P=N/A, N=20, Completed, Sponsor: University of Luebeck
Recruiting --> Completed Trial primary completion date: Oct 2013 --> Jan 2013
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: LucERG: Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD (clinicaltrials.gov) - May 13, 2014
P=N/A, N=20, Completed, Sponsor: University of Luebeck
Trial primary completion date: Oct 2013 --> Jan 2013 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: ReCaLL: Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - May 12, 2014
P4, N=50, Recruiting, Sponsor: GWT-TUD GmbH
Active, not recruiting --> Completed Initiation date: Mar 2014 --> Apr 2014
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: ReCaLL: Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - May 12, 2014
P4, N=50, Recruiting, Sponsor: GWT-TUD GmbH
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: CARE-ROP: Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (clinicaltrials.gov) - May 7, 2014
P2, N=40, Not yet recruiting, Sponsor: University Hospital Freiburg
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema (clinicaltrials.gov) - May 4, 2014
P4, N=40, Recruiting, Sponsor: Shinshu University
- || Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial primary completion date: Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema (clinicaltrials.gov) - May 1, 2014
P2, N=363, Completed, Sponsor: Allergan
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Feb 2014
- || Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial completion date: Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema (clinicaltrials.gov) - May 1, 2014
P2, N=363, Completed, Sponsor: Allergan
Trial primary completion date: Jan 2015 --> Feb 2014 Trial completion date: Jan 2015 --> Feb 2014
- |||| Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial completion: Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema (clinicaltrials.gov) - May 1, 2014
P2, N=363, Completed, Sponsor: Allergan
Trial completion date: Jan 2015 --> Feb 2014 Active, not recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: RIVAL: A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (clinicaltrials.gov) - Apr 30, 2014
P4, N=278, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing (clinicaltrials.gov) - Apr 28, 2014
P2, N=20, Not yet recruiting, Sponsor: Maturi, Raj K., M.D., P.C.
- PF582 (ranibizumab biosimilar) / Ligand
New P1/2 trial: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) - Apr 21, 2014
P1/2, N=24, Recruiting, Sponsor: Pfenex, Inc
- PF582 (ranibizumab biosimilar) / Ligand
Enrollment open: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) - Apr 21, 2014
P1/2, N=24, Recruiting, Sponsor: Pfenex, Inc
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: LUMINOUS: Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=23105, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=30000 --> 23105
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial: Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF (clinicaltrials.gov) - Apr 17, 2014
P1/2, N=145, Completed, Sponsor: California Retina Consultants
- lidocaine topical / Generic mfg.
Trial completion: Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=57, Completed, Sponsor: Retina Vitreous Associates of Florida
N=30000 --> 23105 Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration (clinicaltrials.gov) - Apr 15, 2014
P3, N=426, Completed, Sponsor: Genentech
Recruiting --> Completed No longer recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD (clinicaltrials.gov) - Apr 14, 2014
P3, N=644, Ongoing, Sponsor: Novartis Farmac
No longer recruiting --> Completed Initiation date: Dec 2013 --> Nov 2013
- Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (clinicaltrials.gov) - Apr 13, 2014
P1/2, N=150, Recruiting, Sponsor: Palmetto Retina Center, LLC
Initiation date: Dec 2013 --> Nov 2013 Initiation date: Oct 2013 --> Nov 2013
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: SHIFT-2: Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections (clinicaltrials.gov) - Apr 13, 2014
P4, N=200, Recruiting, Sponsor: Michael Brent
Initiation date: Oct 2013 --> Nov 2013 Initiation date: Dec 2013 --> Apr 2014
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: SHIFT-2: Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections (clinicaltrials.gov) - Apr 13, 2014
P4, N=200, Recruiting, Sponsor: Michael Brent
Initiation date: Dec 2013 --> Apr 2014 Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema (clinicaltrials.gov) - Apr 13, 2014
P1/2, N=150, Recruiting, Sponsor: Palmetto Retina Center, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date, Monotherapy: PROTEUS: Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (clinicaltrials.gov) - Apr 8, 2014
P2/3, N=94, Not yet recruiting, Sponsor: Association for Innovation and Biomedical Research on Light and Image
Not yet recruiting --> Recruiting Initiation date: Jan 2014 --> Apr 2014
- | AVA-101 / Adverum Biotech
Enrollment closed: Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Apr 8, 2014
P1/2, N=40, Active, not recruiting, Sponsor: Lions Eye Institute, Perth, Western Australia
Initiation date: Jan 2014 --> Apr 2014 Recruiting --> Active, not recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab (clinicaltrials.gov) - Apr 7, 2014
P=N/A, N=242, Completed, Sponsor: Maisonneuve-Rosemont Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Combination therapy: Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (clinicaltrials.gov) - Apr 6, 2014
P3, N=691, Completed, Sponsor: Diabetic Retinopathy Clinical Research Network
Active, not recruiting --> Completed Trial completion date: Mar 2013 --> Feb 2014
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy: Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (clinicaltrials.gov) - Apr 6, 2014
P3, N=691, Completed, Sponsor: Diabetic Retinopathy Clinical Research Network
Trial completion date: Mar 2013 --> Feb 2014 Active, not recruiting --> Completed
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date, Monotherapy: Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (clinicaltrials.gov) - Apr 6, 2014
P3, N=454, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Jan 2012 --> May 2012
- || Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: ERASER: Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab (clinicaltrials.gov) - Apr 6, 2014
P2/3, N=60, Not yet recruiting, Sponsor: California Retina Consultants
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Monotherapy: Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (clinicaltrials.gov) - Apr 6, 2014
P3, N=454, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2012 --> May 2012 Recruiting --> Active, not recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Monotherapy: Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (clinicaltrials.gov) - Apr 6, 2014
P3, N=357, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Monotherapy: Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis (clinicaltrials.gov) - Apr 3, 2014
P2, N=54, Completed, Sponsor: Jos
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Beovu (brolucizumab-dbll) / Novartis
Enrollment change: ESBA1008 Microvolume Study (clinicaltrials.gov) - Apr 1, 2014
P2, N=52, Recruiting, Sponsor: Alcon Research
Active, not recruiting --> Completed N=26 --> 52
- |||| PF-655 / SBI Biotech
Trial completion, Combination therapy: MATISSE: PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME) (clinicaltrials.gov) - Mar 27, 2014
P2, N=258, Completed, Sponsor: Quark Pharmaceuticals
N=26 --> 52 Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial initiation date: TAPAS: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (clinicaltrials.gov) - Mar 19, 2014
P2/3, N=55, Recruiting, Sponsor: King's College Hospital NHS Trust
Active, not recruiting --> Completed Initiation date: May 2013 --> Sep 2013
- | Lucentis (ranibizumab) / Roche, Novartis, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: TAPAS: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (clinicaltrials.gov) - Mar 19, 2014
P2/3, N=55, Recruiting, Sponsor: King's College Hospital NHS Trust
Initiation date: May 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial initiation date: Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) - Mar 18, 2014
P2, N=125, Recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
Not yet recruiting --> Recruiting Initiation date: Nov 2013 --> Feb 2014
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Phase II Combination Steroid and Anti-VEGF for Persistent DME (clinicaltrials.gov) - Mar 18, 2014
P2, N=125, Recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
Initiation date: Nov 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Biomarker: MKONDO-CRVO: Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO (clinicaltrials.gov) - Mar 17, 2014
P=N/A, N=30, Recruiting, Sponsor: Mie University
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy (clinicaltrials.gov) - Mar 12, 2014
P2, N=20, Completed, Sponsor: Vitreo-Retinal Associates, PC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Enrollment change: The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot (clinicaltrials.gov) - Mar 9, 2014
P2, N=6, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed N=30 --> 6
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: RAVEN: Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (clinicaltrials.gov) - Mar 6, 2014
P1/2, N=14, Completed, Sponsor: Hanscom, Thomas, M.D.
N=30 --> 6 N=20 --> 14
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: RAVEN: Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (clinicaltrials.gov) - Mar 6, 2014
P1/2, N=14, Completed, Sponsor: Hanscom, Thomas, M.D.
N=20 --> 14 Recruiting --> Completed
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis, Macugen (pegaptanib) / Bausch Health
Enrollment open: Cohort Study of the Clinical Course of Macular Diseases in Japanese (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=1000, Recruiting, Sponsor: Kyoto University, Graduate School of Medicine
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: The TURF Study: Study for Recalcitrant Age Related Macular Degeneration (clinicaltrials.gov) - Mar 3, 2014
P4, N=46, Active, not recruiting, Sponsor: David M. Brown, M.D.
Not yet recruiting --> Recruiting Completed --> Active, not recruiting
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (clinicaltrials.gov) - Feb 22, 2014
P3, N=180, Completed, Sponsor: Genentech
Completed --> Active, not recruiting No longer recruiting --> Completed